Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CCR8 monoclonal antibody RO7502175

A humanized immunoglobulin G1 (IgG1) afucosylated monoclonal antibody directed against C-C-chemokine receptor 8 (CCR8), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CCR8 monoclonal antibody RO7502175 targets and binds to the N-terminus of CCR8 on CCR8-positive, immunosuppressive tumor-infiltrating T regulatory (TITR) cells in the tumor microenvironment (TME). This depletes CCR8-positive TITR cells via antibody-dependent cell-mediated cytotoxicity (ADCC), which may reverse the suppression of CD8+ effector T cells and reactivate antitumor immune responses. CCR8 is specifically expressed by TITR cells in multiple types of cancer and plays a key role in immunosuppression.
Synonym:anti-C-C motif chemokine receptor 8 monoclonal antibody RO7502175
Code name:RO 7502175
RO-7502175
RO7502175
Search NCI's Drug Dictionary